Does anticoagulation with edoxaban reduce cardiovascular death, stroke, or systemic embolism in patients with atrial high-rate episodes detected by implantable devices?
In patients with device-detected atrial high-rate episodes, routine anticoagulation with edoxaban did not reduce thromboembolic events but significantly increased the risk of major bleeding or death.
Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.).
Kirchhof et al. (Fri,) studied this question.